argenex SE $ARGX Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP lowered its position in shares of argenex SE (NASDAQ:ARGX) by 84.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 10,500 shares of the company’s stock after selling 57,423 shares during the quarter. Hudson Bay Capital Management LP’s holdings in argenex were worth $7,744,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Ameriflex Group Inc. acquired a new position in argenex during the third quarter valued at approximately $32,000. Sunbelt Securities Inc. acquired a new stake in shares of argenex in the third quarter worth $36,000. Bessemer Group Inc. raised its stake in shares of argenex by 276.5% in the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after acquiring an additional 47 shares during the period. MAI Capital Management lifted its holdings in shares of argenex by 866.7% during the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after acquiring an additional 78 shares in the last quarter. Finally, Mather Group LLC. acquired a new position in shares of argenex during the 3rd quarter valued at $50,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $663.93 on Friday. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The stock’s 50-day simple moving average is $792.62 and its 200-day simple moving average is $815.26. The firm has a market cap of $41.08 billion, a price-to-earnings ratio of 34.01, a PEG ratio of 1.13 and a beta of 0.38.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. As a group, research analysts predict that argenex SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wells Fargo & Company cut their price objective on argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Guggenheim decreased their target price on argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Morgan Stanley increased their target price on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Finally, Wolfe Research restated a “peer perform” rating on shares of argenex in a report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $999.22.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.